文献速递心外重症与机械循环支持

儿童长期植入式心室辅助装置支持

Long-term implantable ventricular assist device support in children.
PubMed 文献 · J Thorac Cardiovasc Surg · 2023-10-31

单中心回顾性分析2008至2022年100例儿童植入式连续流心室辅助装置(IC-VAD)植入,中位年龄14.1岁。6个月时94%达到积极结局,82%带装置出院回家,出血、感染、卒中发生率出院后较出院前下降。作者认为儿童IC-VAD门诊管理可行,可提供真正长期支持而非仅作为移植前临时过渡。

要点

  • 100例IC-VAD植入中,心肌病58例、先天性心脏病37例(含单心室13例)。
  • 6个月时94例达到积极结局:持续支持59例、移植33例、心脏恢复2例。
  • 82例带VAD出院回家,其中38例再入院、7例死亡。

核心结论

  • 本研究提示儿童IC-VAD支持的门诊管理具有可行性。
  • 提供真正长期支持的能力最大化了IC-VAD支持的潜力,而不限于作为心脏移植的临时桥接工具。

研究设计与样本

  • 回顾性综述,纳入2008年至2022年在一家三级儿童心脏中心连续接受IC-VAD支持的患者。
  • 共100例IC-VAD植入:HeartWare HVAD 67例(67%)、HeartMate II 17例(17%)、HeartMate 3 16例(16%)。
  • 植入时中位(范围)年龄14.1(3.0-56.5)岁、体重54.8(13.3-140)kg、体表面积1.6(0.6-2.6)m2。

主要发现

  • 心肌病58例(58%)最常见,其次为先天性心脏病37例(37%,包括13例单心室)。
  • IC-VAD支持6个月时,94例(94%)达到积极结局:持续支持59例(59%)、移植33例(33%)、心脏恢复2例(2%)。
  • 82例(82%)带VAD支持出院回家,其中38例(46%,占82例)需再入院、7例(9%,占82例)死亡。
  • 出院回家前后发病率有临床显著下降:出血(1.55 vs 0.06事件/患者年)、感染(0.84 vs 0.37事件/患者年)、卒中(0.84 vs 0.15事件/患者年)。
  • 最新随访时86例(86%)达到积极终点(移植64例、持续支持15例、恢复7例);负性结局最常见原因为感染(29%;4/14),其次为脑血管意外(21%;3/14)和未解决的衰弱(21%;3/14)。

临床怎么用

  • 作者认为儿童IC-VAD支持的门诊管理具有可行性,可提供真正长期支持而非仅作为移植前临时桥接。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In pediatrics, implantable continuous-flow ventricular assist devices (IC-VAD) are often used as a "temporary" support, bridging children to cardiac transplantation during the same hospital admission. METHODS: We conducted a retrospective review of our consecutive patients undergoing IC-VAD support at a tertiary pediatric heart center between 2008 and 2022. RESULTS: We identified 100 IC-VAD implant encounters: HeartWare HVAD (67; 67%), HeartMate II (17; 17%), and HeartMate 3 (16; 16%). The median (range) age, weight, and body surface area at implantation were 14.1 (3.0-56.5) years, 54.8 (13.3-140) kg, and 1.6 (0.6-2.6) m2, respectively. Cardiomyopathy (58; 58%) was the most common etiology, followed by congenital heart disease (37; 37%, including 13 single ventricle). At 6 months of IC-VAD support, 94 (94%) encounters achieved positive outcomes: ongoing support (59; 59%), transplant (33; 33%), and cardiac recovery (2; 2%). Eighty-two encounters (82%) resulted in home discharge with ongoing VAD support, including 38 (46%, out of 82) requiring readmission and 7 (9%, out of 82) resulting in death. There was a clinically significant decrease in morbidity rates before versus after home discharge: bleeding (1.55 vs 0.06), infection (0.84 vs 0.37), and stroke (0.84 vs 0.15 event per patient-year). Overall, 86 encounters (86%) reached positive end points at the latest follow-up (64 transplant, 15 ongoing support, and 7 recovery). Infection (29%; 4 of 14) was the most common cause of negative outcomes, followed by cerebrovascular accident (21%; 3), and unresolved frailty (21%; 3). The estimated overall survival at 1, 2, and 5 years was 90%, 86%, and 77%, respectively. CONCLUSIONS: This study suggests the feasibility of outpatient management of pediatric IC-VAD support. The ability to offer true long-term support maximizes the potential of IC-VAD support, not limited to a temporary bridging tool for heart transplantation.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Cho J, Tunuguntla HP, Tume SC, et al. Long-term implantable ventricular assist device support in children. J Thorac Cardiovasc Surg. 2023. PMID: 37913838. doi:10.1016/j.jtcvs.2023.10.048

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。